{"schema_version":"1","generated_at":"2026-10-28T07:13:35.526Z","data_as_of":"2026-10-18","url":"https://www.findmykol.com/kol/kenneth-marek","json_url":"https://www.findmykol.com/kol/kenneth-marek/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"kenneth-marek","name":"Kenneth Marek","credential":"MD","title":"President and Senior Scientist, Institute for Neurodegenerative Disorders; Clinical Professor of Neurology, Yale University","specialty":"Neurology","specialty_raw":"Neurology","therapeutic_area":"Neurology","therapeutic_areas":["Neurology"],"institution":"Institute for Neurodegenerative Disorders","institution_url":"https://www.findmykol.com/institution/institute-for-neurodegenerative-disorders","city":"New Haven","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1467543728","orcid":"0000-0002-4197-5627","openalex":"A5091194111"},"summary":"Kenneth Marek is President and Senior Scientist, Institute for Neurodegenerative Disorders; Clinical Professor of Neurology, Yale University at Institute for Neurodegenerative Disorders. OpenAlex indexes 409 publications with 32,438 citations (h-index 81); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the FindMyKOL directory.","overview":{"text":"Kenneth Marek, MD, is President and Senior Scientist, Institute for Neurodegenerative Disorders. The public record shows 409 publications with 32,438 citations (h-index 81), centered on Parkinson's Disease Mechanisms and Treatments, Dementia and Cognitive Impairment Research, Neurological disorders and treatments. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 9 companies, 3 NIH-funded awards (1990–2001).","bullets":["Most recent indexed publication: 2026 · Annals of neurology","Top research focus: Parkinson's Disease Mechanisms and Treatments","11 registered trials on ClinicalTrials.gov","Open Payments reporting from 9 companies"],"generated_at":"2026-10-27"},"focus":{"indications":[{"label":"Parkinson's Disease","therapeutic_area":"Neurology","trials":11,"topics":1,"strength":34},{"label":"Alzheimer's / Dementia","therapeutic_area":"Neurology","trials":0,"topics":2,"strength":2}],"research_topics":["Parkinson's Disease Mechanisms and Treatments","Dementia and Cognitive Impairment Research","Neurological disorders and treatments","Medical Imaging Techniques and Applications","Alzheimer's disease research and treatments"],"drugs_studied":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"Florbetapir","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":13,"shown":3,"withheld":10,"rows":[{"name":"Eli Lilly and Company","trials":0,"payments":7,"mentions":7},{"name":"F. Hoffmann-La Roche AG","trials":0,"payments":7,"mentions":7},{"name":"Institute for Neurodegenerative Disorders","trials":7,"payments":0,"mentions":7}]}},"scholarship":{"works_count":409,"cited_by_count":32438,"h_index":81,"i10_index":216,"pubmed_count":7,"latest_activity_year":2026,"citation_standing":{"top_percent":5,"cohort":"Neurology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":11,"shown":3,"withheld":8,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT05065060","title":"Parkinson Progression Marker Initiative Online (PPMI Online)","status":"RECRUITING","role":"Investigator","sponsor":"Michael J. Fox Foundation for Parkinson's Research","source_url":"https://clinicaltrials.gov/study/NCT05065060","trial_url":"https://www.findmykol.com/trial/NCT05065060"},{"nct":"NCT04477785","title":"PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort","status":"RECRUITING","role":"Investigator","sponsor":"Michael J. Fox Foundation for Parkinson's Research","source_url":"https://clinicaltrials.gov/study/NCT04477785","trial_url":"https://www.findmykol.com/trial/NCT04477785"},{"nct":"NCT01264861","title":"A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging","phase":"PHASE2","status":"TERMINATED","role":"Investigator","sponsor":"Newron Pharmaceuticals SPA","source_url":"https://clinicaltrials.gov/study/NCT01264861","trial_url":"https://www.findmykol.com/trial/NCT01264861"}],"source":"trials"},"payments":{"company_count":9,"program_years":{"first":2021,"last":2025},"rows_total":12,"shown":3,"withheld":9,"rows":[{"payer":"Eli Lilly and Company","program_year":2025,"amount_usd":12493,"payment_count":6,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467543728"},{"payer":"UCB SA","program_year":2025,"amount_usd":4950,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467543728"},{"payer":"F. Hoffmann-La Roche AG","program_year":2024,"amount_usd":3400,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467543728"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1467543728","source":"payments"},"funding":{"award_count":3,"fiscal_years":{"first":1990,"last":2001},"rows_total":22,"shown":3,"withheld":19,"rows":[{"project":"R01NS036197","title":"(123 I) B CIT SPECT IN PARKINSONS DISEASE PROGRESSION","fiscal_year":2001,"amount_usd":252543,"organization":"INSTITUTE FOR NEURODEGENERATIVE DISORDRS","source_url":"https://reporter.nih.gov/quickSearch/R01NS036197"},{"project":"R01NS036197","title":"(123 I) B CIT SPECT IN PARKINSONS DISEASE PROGRESSION","fiscal_year":2001,"amount_usd":45660,"organization":"YALE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01NS036197"},{"project":"M01RR000125","title":"ASSESSMENT OF MOTOR AND NONMOTOR DEFICITS IN PARKINSON'S AND RELATED DISEASES","fiscal_year":2001,"organization":"YALE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/M01RR000125"}],"source":"grants"},"publications":{"total":7,"shown":5,"withheld":2,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"An Introduction to the Special Issue from the Editors.","year":2026,"journal":"Annals of neurology","types":["Editorial"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42788383/","status":"verified"},{"title":"α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.","year":2025,"journal":"Neurology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39913882/","status":"verified"},{"title":"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.","year":2024,"journal":"medRxiv : the preprint server for health sciences","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39314957/","status":"verified"},{"title":"LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Alpha-Synuclein Aggregates.","year":2024,"journal":"medRxiv : the preprint server for health sciences","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39108519/","status":"verified"},{"title":"Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.","year":2024,"journal":"Neurology","types":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38306599/","status":"verified"}],"most_cited":{"total":409,"shown":5,"withheld":404,"rows":[{"title":"MDS clinical diagnostic criteria for Parkinson's disease","year":2015,"cited_by_count":7600,"type":"article","source_url":"https://doi.org/10.1002/mds.26424"},{"title":"The Parkinson Progression Marker Initiative (PPMI)","year":2011,"cited_by_count":1901,"type":"article","source_url":"https://doi.org/10.1016/j.pneurobio.2011.09.005"},{"title":"MDS research criteria for prodromal Parkinson's disease","year":2015,"cited_by_count":1311,"type":"article","source_url":"https://doi.org/10.1002/mds.26431"},{"title":"Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy","year":2017,"cited_by_count":854,"type":"article","source_url":"https://doi.org/10.1002/mds.27115"},{"title":"Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial","year":2000,"cited_by_count":800,"type":"article","source_url":"https://openalex.org/A5091194111"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"John Peter Seibyl","coauthored_works":185},{"name":"Danna L. Jennings","coauthored_works":93},{"name":"Tanya Simuni","coauthored_works":71}],"source":"works"},"presence":{"mentions":{"total":3,"shown":3,"rows":[{"url":"https://gp2.org/individuals/kenneth-marek/","platform":"other","status":"verified"},{"url":"https://www.michaeljfox.org/researcher/kenneth-marek-md","platform":"other","status":"verified"},{"url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":4,"shown":4,"rows":[{"value":"AB in Biochemistry, Princeton University","source_url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","status":"verified","collected_at":"2026-10-26"},{"value":"MD, Yale University","source_url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","status":"verified","collected_at":"2026-10-26"},{"value":"Postdoctoral fellowship in neurochemistry, Institute of Neurology, London","source_url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","status":"verified","collected_at":"2026-10-26"},{"value":"Board certified in Internal Medicine and Neurology","source_url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","status":"provisional","collected_at":"2026-10-26"}]},"roles":{"total":2,"shown":2,"rows":[{"value":"Special Scientific Advisor, The Michael J. Fox Foundation","source_url":"https://www.michaeljfox.org/publication/michael-j-fox-foundation-announces-kenneth-marek-md-has-joined-staff-scientific-advisor","status":"verified","collected_at":"2026-10-26"},{"value":"Member, Steering Committee, GP2 (Genetic Park 2)","source_url":"https://gp2.org/individuals/kenneth-marek/","status":"verified","collected_at":"2026-10-26"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"Robert A. Pritzker Prize for Leadership in Parkinson's Research","source_url":"https://www.michaeljfox.org/publication/michael-j-fox-foundation-honors-ken-marek-md-robert-pritzker-prize-leadership","status":"verified","collected_at":"2026-10-26"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Yale University School of Medicine, Department of Neurology","source_url":"https://www.ppmi-info.org/about-ppmi/who-we-are/ken-marek","status":"verified","collected_at":"2026-10-26"}]}},"similar":[{"name":"Thomas Tropea","slug":"thomas-tropea","institution":"Institute for Neurodegenerative Disorders","specialty":"Neurology","url":"https://www.findmykol.com/kol/thomas-tropea","json_url":"https://www.findmykol.com/kol/thomas-tropea/profile.json"},{"name":"Bruce Miller","slug":"bruce-miller","institution":"University of California, San Francisco (UCSF)","specialty":"Neurology","url":"https://www.findmykol.com/kol/bruce-miller","json_url":"https://www.findmykol.com/kol/bruce-miller/profile.json"},{"name":"Brett Kissela","slug":"brett-kissela","institution":"Medical College of Wisconsin","specialty":"Neurology","url":"https://www.findmykol.com/kol/brett-kissela","json_url":"https://www.findmykol.com/kol/brett-kissela/profile.json"},{"name":"Bradley Boeve","slug":"bradley-boeve","institution":"Mayo Clinic","specialty":"Neurology","url":"https://www.findmykol.com/kol/bradley-boeve","json_url":"https://www.findmykol.com/kol/bradley-boeve/profile.json"},{"name":"Richard Lipton","slug":"richard-lipton","institution":"Albert Einstein College of Medicine","specialty":"Neurology","url":"https://www.findmykol.com/kol/richard-lipton","json_url":"https://www.findmykol.com/kol/richard-lipton/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":8,"payments":9,"funding":19,"publications":2,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-26"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-26"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-26"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-26"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-26"}},"methodology_url":"https://www.findmykol.com/about#methodology"}